Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 9/20 | 0.47 |
| ▸ | FLT3 | P36888 | 9/20 | 0.47 |
| ▸ | CCNA1 | P78396 | 9/20 | 0.47 |
| ▸ | STING1 | Q86WV6 | 1/20 | 0.45 |
| ▸ | KDR | P35968 | 1/20 | 0.42 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.42 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.42 |
| ▸ | PBK | Q96KB5 | 1/20 | 0.41 |
| ▸ | ESR1 | P03372 | 3/20 | 0.40 |
| ▸ | ESR2 | Q92731 | 3/20 | 0.40 |
| ▸ | KIF11 | P52732 | 1/20 | 0.39 |
| ▸ | HASPIN | Q8TF76 | 1/20 | 0.39 |
| ▸ | DRD4 | P21917 | 1/20 | 0.38 |
| ▸ | NOS1 | P29475 | 3/20 | 0.38 |
| ▸ | AXL | P30530 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24179543 | 0.78 | ESR1 (0.49) | CDK2FLT3CCNA1ESR1ESR2 | |
| SCHEMBL21219144 | 0.76 | ESR1 (0.41) | CDK2FLT3CCNA1ESR1ESR2 | |
| SCHEMBL30970847 | 0.74 | FLT3 (0.54) | CDK2FLT3CCNA1STING1PBK | |
| SCHEMBL22478076 | 0.74 | FLT3 (0.54) | CDK2FLT3CCNA1STING1PBK | |
| SCHEMBL2940438 | 0.72 | NOS1 (0.36) | CDK2FLT3CCNA1STING1KDR | |
| SCHEMBL29424626 | 0.72 | MAOA (0.43) | ESR2DRD4 | |
| SCHEMBL26130378 | 0.71 | HTR2A (0.42) | CDK2FLT3CCNA1STING1MAPK10 | |
| SCHEMBL24459190 | 0.71 | ESR2 (0.46) | ESR1ESR2 | |
| SCHEMBL19118540 | 0.71 | IDO1 (0.40) | CDK2FLT3CCNA1STING1KDR | |
| SCHEMBL12321248 | 0.71 | NOS1 (0.56) | CDK2CCNA1NOS1AXL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180099939-A1 | COMPOUNDS AND METHODS FOR IDO AND TDO MODULATION AND INDICATIONS THEREFOR | PLEXXIKON INC. | 2018-04-12 | — | — | US | disclosed |
| WO-2018057973-A1 | COMPOUNDS AND METHODS FOR IDO AND TDO MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC. (US) | 2018-03-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180099939-A1 | COMPOUNDS AND METHODS FOR IDO AND TDO MODULATION AND INDICATIONS THEREFOR | IDO1, TDO2, IDO2 | CDK2 425/4885FLT3 910/4885CCNA1 476/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.